Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Beam Therapeutics Inc Market Cap
From what 18 stock analysts predict, the share price for Beam Therapeutics Inc (BEAM) might increase by 78.78% in the next year. This is based on a 12-month average estimation for BEAM. Price targets go from $23 to $80. The majority of stock analysts believe BEAM is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 18 Wall Street analysts have assigned BEAM 10 buy ratings, 8 hold ratings, and 0 sell ratings. This means that analysts expect Beam Therapeutics Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on BEAM. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of BEAM.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Patrick Trucchio HC Wainwright & Co. | Buy | $80 | Reiterates | Dec 9, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $80 | Reiterates | Nov 7, 2024 |
| Rick Bienkowski Leerink Partners | Outperform | $39 | Upgrade | Nov 6, 2024 |
| Luca Issi RBC Capital | Sector Perform | $24 | Maintains | Nov 6, 2024 |
| Greg Harrison Scotiabank | Sector Perform | $24 | Initiates | Oct 16, 2024 |
| Luca Issi RBC Capital | Sector Perform | $27 | Reiterates | Sep 19, 2024 |
| Soumit Roy Jones Trading | Hold | Initiates | Sep 17, 2024 | |
| Benjamin Burnett Stifel | Buy | $69 | Maintains | Sep 11, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $80 | Reiterates | Aug 22, 2024 |
| Luca Issi RBC Capital | Sector Perform | $27 | Reiterates | Aug 7, 2024 |
| Eric Joseph JP Morgan | Overweight | $48 | Maintains | Aug 7, 2024 |
| Gena Wang Barclays | Equal-Weight | $31 | Maintains | Aug 7, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $80 | Initiates | Jul 23, 2024 |
| Gena Wang Barclays | Equal-Weight | $33 | Maintains | May 8, 2024 |
| David Nierengarten Wedbush | Outperform | $57 | Reiterates | Apr 23, 2024 |
| Kostas Biliouris BMO Capital | Outperform | $57 | Maintains | Mar 27, 2024 |
| Luca Issi RBC Capital | Sector Perform | $35 | Maintains | Feb 28, 2024 |
| Gena Wang Barclays | Equal-Weight | $42 | Maintains | Feb 28, 2024 |
| Eric Joseph JP Morgan | Overweight | $40 | Upgrade | Jan 29, 2024 |
| Greg Harrison B of A Securities | Neutral | $35 | Downgrade | Dec 15, 2023 |
When did it IPO
2020
Staff Count
472
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. John M. Evans M.B.A.
Market Cap
$2.28B
In 2023, BEAM generated $377.7M in revenue, which was a increase of 520.01% from the previous year. This can be seen as a signal that BEAM's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 09 Dec 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - BEAM has appointed Sravan K. Emany as its new chief financial officer, effective December 19.
Why It Matters - Leadership changes can impact company strategy and performance. A new CFO may signal shifts in financial management, affecting investor confidence and stock valuation.
Sun, 08 Dec 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - NHP data indicate that CD117 monoclonal antibody conditioning effectively enabled long-term engraftment of base-edited hematopoietic stem cells and increased Hemoglobin F levels.
Why It Matters - Successful long-term engraftment of base-edited hematopoietic stem cells suggests advancements in gene therapies, potentially boosting biotech stock valuations and attracting investment in innovative treatments.
Sat, 07 Dec 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - All seven patients treated with BEAM-101 demonstrated over 60% induction of Hemoglobin F (HbF) and a reduction in Hemoglobin S (HbS), indicating positive treatment outcomes.
Why It Matters - Successful HbF induction and HbS reduction in all patients treated with BEAM-101 indicate strong potential for the therapy, likely boosting company stock and attracting investor interest in biotech.
Fri, 06 Dec 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Beam Therapeutics Inc. has appointed Sravan K. Emany as CFO, effective December 19, 2024. Emany has extensive experience in global operations and finance, previously serving at Ironwood Pharmaceuticals.
Why It Matters - The appointment of a new CFO with extensive experience may signal strategic shifts at Beam Therapeutics, potentially impacting financial stability and growth prospects, influencing investor sentiment.
Thu, 05 Dec 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Beam Therapeutics (BEAM) reported earnings 30 days ago; investors should monitor upcoming developments and market reactions for potential stock movements.
Why It Matters - Earnings reports can signal company performance trends, impacting stock price. Investors will watch for guidance on future growth and potential market reactions.
Wed, 04 Dec 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Beam Therapeutics Inc. appointed Chirfi Guindo, Merck's chief marketing officer, to its board of directors. Guindo has over 25 years of experience in the pharmaceutical industry.
Why It Matters - Chirfi Guindo's appointment enhances Beam Therapeutics' leadership with extensive pharmaceutical experience, potentially boosting strategic direction and investor confidence in its growth prospects.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
